Payment overview · 2025
General Payments
$1,264.26
29 reported records · 24 companies
Healthcare provider profile · identity verified
David B Hevert, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BOCA RATON, FL · NPI 1184700775
Verified facts
What the public records show
CMS Open Payments records show David B Hevert, MD received $1,264.26 in general payments during 2025 across 29 reported records.
Abbott Laboratories accounted for 14.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Brilinta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 278 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $180.48 | 14.3% | 1 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $170.90 | 13.5% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $144.76 | 11.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $121.51 | 9.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $118.74 | 9.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $66.56 | 5.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.71 | 3.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.81 | 3.7% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $31.32 | 2.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.14 | 2.4% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $27.72 | 2.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.43 | 2.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.45 | 2.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.45 | 2.0% | 1 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $25.23 | 2.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.63 | 1.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.94 | 1.7% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $21.39 | 1.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.49 | 1.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.62 | 1.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.67 | 1.4% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.03 | 1.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $16.36 | 1.3% | 1 | 2025 |
| Medicure Pharma Inc. | Unresolved — no canonical attribution shown | $14.92 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,264.26 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $180.48 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $170.90 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $170.90 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $145.17 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $144.76 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $121.51 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $66.56 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $33.66 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $33.66 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $31.32 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.14 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $27.72 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.63 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| Zypitamag Normalized: zypitamag |
Drug | Medicure Pharma Inc. | $14.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 17 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
106 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
278 | 60 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 760 | 215 |
| Levothyroxine Sodium | Levothyroxine Sodium | 578 | 135 |
| Atorvastatin Calcium | Atorvastatin Calcium | 493 | 124 |
| Ezetimibe | Ezetimibe | 426 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 407 | 110 |
| Losartan Potassium | Losartan Potassium | 302 | 83 |
| Eliquis | Apixaban | 278 | 60 |
| Furosemide | Furosemide | 258 | 71 |
| Trazodone Hcl | Trazodone Hcl | 257 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 233 | 66 |
| Gabapentin | Gabapentin | 232 | 49 |
| Xarelto | Rivaroxaban | 227 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 220 | 63 |
| Metformin Hcl | Metformin Hcl | 218 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 53 |
| Azithromycin | Azithromycin | 199 | 136 |
| Donepezil Hcl | Donepezil Hcl | 189 | 45 |
| Potassium Chloride | Potassium Chloride | 182 | 51 |
| Lisinopril | Lisinopril | 172 | 46 |
| Methylprednisolone | Methylprednisolone | 156 | 117 |
| Simvastatin | Simvastatin | 155 | 40 |
| Famotidine | Famotidine | 154 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 43 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 129 | 83 |
| Mirtazapine | Mirtazapine | 129 | 36 |
| Montelukast Sodium | Montelukast Sodium | 125 | 30 |
| Spironolactone | Spironolactone | 117 | 39 |
| Omeprazole | Omeprazole | 112 | 29 |
| Alendronate Sodium | Alendronate Sodium | 110 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 37 |
| Alprazolam | Alprazolam | 106 | 44 |
| Mounjaro | Tirzepatide | 106 | 20 |
| Carvedilol | Carvedilol | 103 | 28 |
| Vascepa | Icosapent Ethyl | 102 | 29 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 101 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 29 |
| Memantine Hcl | Memantine Hcl | 92 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 20 |
| Tramadol Hcl | Tramadol Hcl | 91 | 30 |
| Finasteride | Finasteride | 87 | 23 |
| Bumetanide | Bumetanide | 84 | 16 |
| Cefuroxime | Cefuroxime Axetil | 84 | 62 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 83 | 26 |
| Allopurinol | Allopurinol | 80 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 76 | 28 |
| Entresto | Sacubitril/Valsartan | 75 | 15 |
| Prednisone | Prednisone | 73 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 16 |
| Mupirocin | Mupirocin | 72 | 46 |
| Meloxicam | Meloxicam | 71 | 24 |
| Sertraline Hcl | Sertraline Hcl | 71 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | 21 |
| Synthroid | Levothyroxine Sodium | 63 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 45 |
| Midodrine Hcl | Midodrine Hcl | 62 | 17 |
| Lactulose | Lactulose | 60 | 15 |
| Lorazepam | Lorazepam | 59 | 19 |
| Jardiance | Empagliflozin | 56 | suppressed |
| Latanoprost | Latanoprost | 56 | 17 |
| Divalproex Sodium | Divalproex Sodium | 54 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 54 | 12 |
| Januvia | Sitagliptin Phosphate | 52 | suppressed |
| Valsartan | Valsartan | 51 | 12 |
| Atenolol | Atenolol | 50 | 15 |
| Bupropion Xl | Bupropion Hcl | 50 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 48 | 20 |
| Levetiracetam | Levetiracetam | 48 | 12 |
| Baclofen | Baclofen | 47 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | 11 |
| Cephalexin | Cephalexin | 45 | 31 |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | suppressed |
| Levofloxacin | Levofloxacin | 43 | 31 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 42 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 42 | suppressed |
| Clonazepam | Clonazepam | 41 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 40 | 39 |
| Buspirone Hcl | Buspirone Hcl | 40 | 16 |
| Temazepam | Temazepam | 40 | 14 |
| Clonidine Hcl | Clonidine Hcl | 39 | 22 |
| Timolol Maleate | Timolol Maleate | 38 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 37 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 36 | 13 |
| Procrit | Epoetin Alfa | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 16 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 33 | 33 |
| Nystatin | Nystatin | 33 | 17 |
| Oxycontin | Oxycodone Hcl | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 18 |
| Valacyclovir | Valacyclovir Hcl | 32 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 17 |
| Brilinta | Ticagrelor | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | 12 |
| Diazepam | Diazepam | 29 | 14 |
| Metformin Hcl Er | Metformin Hcl | 29 | 11 |
| Ondansetron Odt | Ondansetron | 29 | 15 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 28 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Multaq | Dronedarone Hcl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Xifaxan | Rifaximin | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 18 |
| Nitroglycerin | Nitroglycerin | 26 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 20 |
| Cholestyramine | Cholestyramine (With Sugar) | 25 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Novolog | Insulin Aspart | 22 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 22 | 21 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Klor-Con 10 | Potassium Chloride | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | 11 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Repaglinide | Repaglinide | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 17 |
| Albuterol Sulfate | Albuterol Sulfate | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Budesonide | Budesonide | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 18 | 12 |
| Colchicine | Colchicine | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 11 |
| Livalo | Pitavastatin Calcium | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Epogen | Epoetin Alfa | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Buprenorphine | Buprenorphine | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Ertapenem | Ertapenem Sodium | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Tradjenta | Linagliptin | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,264.26 · 29 records | Abbott Laboratories | ABRYSVO, AVEIR, BREZTRI, Barostim Neo System, CAPVAXIVE, COMIRNATY, Cleerly Ischemia, Cleerly Labs, Cologuard Collection Kit, EVENITY, Evoke, FFRct, Fluad, Flucelvax, GARDASIL 9, GEMTESA, JARDIANCE, Leqembi, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Tymlos, UBRELVY, Veozah, WATCHMAN FLX, Wegovy, XIFAXAN, Xhance, Zypitamag | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error